NCT01383733View on ClinicalTrials.gov

A Study of RO5458640 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Neoplasms
Interventions
DRUG

RO5458640

Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks

Trial Locations (4)

2100

København Ø

K1H 8L6

Ottawa

M5G 2M9

Toronto

1066 CX

Amsterdam

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01383733 - A Study of RO5458640 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter